3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Drug News -

Perrigo recalls oral drops for children in U.S.

Drug NewsAug 02, 05

Perrigo Co. voluntarily recalled four types of liquid pain, cough and cold drops packaged with syringes that could make it difficult to measure proper doses for young children, the company and regulators said on Monday.

Perrigo said the recall would cost the company about $2 million.

The recalled products are Cherry Flavor Infant Pain Reliever 160 mg Acetaminophen (0.5 oz. and 1.0 oz.), Grape Flavor Infant Pain Reliever 160 mg Acetaminophen (0.5 oz. and 1.0 oz.), Cherry Flavor Cough and Cold Infant Drops (0.5 oz.) and Cherry Flavor Decongestant and Cough Infant Drops (0.5 oz.).

The oral syringes distributed with the over-the-counter medicines were not marked to measure doses less than 1.6 milliliter, which may be prescribed for children younger than 2 and less than 24 pounds, the Food and Drug Administration said in a statement.

Ingesting too much acetaminophen, a pain-relieving ingredient, may cause liver damage, the FDA said.

The products were distributed nationally at retail chains under 34 different store-brand labels including CVS, Target Corp. and Walgreen Co., the FDA said.

Until recently, the pain relievers had been distributed with droppers that had different markings, the FDA said.

The change and the new markings “caused some confusion among consumers and health-care professionals and may lead to improper dosing,” the FDA said.

Perrigo, in a filing with securities regulators, said the value of its on-hand inventories and the cost of return and disposal are estimated to be about $2 million and will be recorded in the fiscal 2005 fourth quarter that ended June 25.

Shares of Allegan, Michigan-based Perrigo gained 7 cents to close at $13.97 on Nasdaq.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  UGA ecologist finds another cause of antibiotic resistance
  New drug for neuroblastoma shows promise in phase I study
  Baclofen shows promise in patients with alcohol-induced liver disease
  Findings point to an ‘off switch’ for drug resistance in cancer
  Stopping statins may benefit terminally ill patients
  Cholesterol drug users may use pills as a license to overeat
  Pfizer lung cancer drug beats chemo for previously untreated patients
  Mass. General study identifies path to safer drugs for heart disease, cancer
  Gates Foundation awards Notre Dame $23 million for malaria, dengue studies
  Cancer drug protects against diabetes
  Malaria drug target raises hopes for new treatments

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site